Amyloid Mimicking Myeloma: A Diagnostic Trap

Shivangi Dikshit; Sukanta Barai; Deepa Thulasikumar Sunitha

doi:10.1055/s-0045-1813680

World Journal of Nuclear Medicine, Table of Contents

CC BY 4.0 · World J Nucl Med
DOI: 10.1055/s-0045-1813680

Case Report

Amyloid Mimicking Myeloma: A Diagnostic Trap

Authors

Shivangi Dikshit

¹Department of Nuclear Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Sukanta Barai

¹Department of Nuclear Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Deepa Thulasikumar Sunitha

¹Department of Nuclear Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

Abstract

We present the case of a 54-year-old male with relapsing multiple myeloma (MM) complicated by biopsy-proven amyloid deposition, monitored over a span of 13 years with serial ¹⁸F-FDG PET/CT imaging. The patient experienced multiple treatment interruptions and disease relapses, with evolving imaging features ranging from widespread skeletal involvement to soft tissue plasmacytoma formation and associated amyloid deposition. This case highlights the evolving role of ¹⁸F-FDG PET/CT in detecting disease progression and treatment response in plasma cell dyscrasias with coexisting amyloidosis.

Keywords

¹⁸F-FDG PET/CT - multiple myeloma - amyloid - plasmacytoma - paramedullary

Full Text

References

References
1 Cavo M, Terpos E, Nanni C. et al. Role of ¹⁸F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017; 18 (04) e206-e217
2 Patriarca F, Zaja F, Silvestri F. et al. Clinical implications of extramedullary disease in multiple myeloma patients treated with novel agents. Haematologica 2005; 90 (11) 1617-1619
3 Kim PJ, Kim SJ, Lee JW, Jeong SY, Kim HJ, Min JJ. Clinical characteristics and PET/CT findings of extramedullary versus medullary relapse in multiple myeloma. Clin Nucl Med 2021; 46 (07) e343-e349
4 Fontana M, Pica S, Rezk T. et al. Prognostic value of 18F-FDG PET/CT in systemic AL amyloidosis. Eur J Nucl Med Mol Imaging 2019; 46 (07) 1541-1548
5 Muchtar E, Dispenzieri A, Kumar SK. et al. Interplay between AL amyloidosis and multiple myeloma: impact of light chain type on disease characteristics, treatment, and outcomes. Leukemia 2019; 33 (02) 525-531
6 Bahlis NJ, Lazarus HM. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?. Bone Marrow Transplant 2006; 38 (01) 7-15
7 Kyle RA, Larson DR, Kurtin PJ. et al. Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc 2019; 94 (03) 465-471
8 Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 2022; 97 (08) 1086-1107
9 Bhutani D, Patel K, Foureau DM. et al. Prognostic significance of extramedullary disease in multiple myeloma: meta-analysis and clinical perspective. Blood Cancer J 2020; 10 (02) 17
10 Sachpekidis C, Kopp-Schneider A, Merz M, Raab MS, Dimitrakopoulou-Strauss A. Longitudinal FDG PET/CT analysis in patients with relapsed multiple myeloma undergoing therapy: predictive and prognostic implications. Clin Nucl Med 2021; 46 (04) e192-e198